Exploring the Efficacy of Alirocumab and Evolocumab in Reducing Low-Density Lipoprotein (LDL) Cholesterol Levels in Patients With Familial Hypercholesterolemia: A Systematic Review.
alirocumab
evolocumab
familial hypercholesterolemia
ldl cholesterol
pcsk-9 inhibitor
Journal
Cureus
ISSN: 2168-8184
Titre abrégé: Cureus
Pays: United States
ID NLM: 101596737
Informations de publication
Date de publication:
Sep 2022
Sep 2022
Historique:
received:
27
06
2022
accepted:
07
09
2022
entrez:
14
10
2022
pubmed:
15
10
2022
medline:
15
10
2022
Statut:
epublish
Résumé
Patients with familial hypercholesterolemia (FH) have an increased risk of having abnormally high low-density lipoprotein cholesterol (LDL-C) levels. One of the main groups of drugs used for FH is statins. However, even with statins, most patients with FH do not achieve their pre-defined therapeutic LDL-C goals. Therefore, proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9i) serve to decrease LDL-C levels in that population. A total of 838 articles were found after searching the databases of PubMed, MEDLINE, and Cochrane Library. After including only full-text peer-reviewed articles published in the last 10 years, 67 articles remained. Thirteen articles were put through the Cochrane bias assessment tool to screen for bias. After a strict quality assessment based on the criteria, eight articles were extracted and included in this systematic review. The data extraction from these studies showed that alirocumab and evolocumab were efficacious in decreasing LDL-C levels and achieving the pre-defined LDL-C goals. Many parameters influenced the strength of the LDL-C reduction: sample size of the population, genetic structure of the patients affected by FH, length of the trial, or baseline lipid-lowering therapy used. Therefore, one must consider several other factors while evaluating the percent reduction of PCSK9i. This review is limited because it did not comment on these drugs' cardiovascular outcomes or mortality benefits. In addition, some of the articles used in this systematic review have small sample sizes and short trial times, limiting the long-term evaluation of these drugs.
Identifiants
pubmed: 36237809
doi: 10.7759/cureus.28930
pmc: PMC9547534
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
e28930Informations de copyright
Copyright © 2022, Luthra et al.
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
J Atheroscler Thromb. 2018 Aug 1;25(8):751-770
pubmed: 29877295
Lancet. 2015 Jan 24;385(9965):331-40
pubmed: 25282519
J Am Coll Cardiol. 2020 Jul 14;76(2):131-142
pubmed: 32646561
BMJ. 2021 Mar 29;372:n71
pubmed: 33782057
Dental Press J Orthod. 2014 Jul-Aug;19(4):27-9
pubmed: 25279518
J Clin Lipidol. 2015 Mar-Apr;9(2):129-69
pubmed: 25911072
Curr Atheroscler Rep. 2015;17(2):482
pubmed: 25612857
N Engl J Med. 2020 Oct 1;383(14):1317-1327
pubmed: 32865373
Lancet. 2015 Jan 24;385(9965):341-50
pubmed: 25282520
Circulation. 2016 Apr 5;133(14):e587-9
pubmed: 27045133
Atherosclerosis. 2010 Mar;209(1):189-94
pubmed: 19818960
J Cardiol. 2018 Jan;71(1):1-7
pubmed: 28784313
Atherosclerosis. 2014 May;234(1):136-41
pubmed: 24637413
Eur Heart J. 2015 Nov 14;36(43):2996-3003
pubmed: 26330422
Pediatrics. 1987 Nov;80(5 Pt 2):807-16
pubmed: 3670991
J Clin Lipidol. 2017 Jan - Feb;11(1):195-203.e4
pubmed: 28391886
J Clin Lipidol. 2017 Nov - Dec;11(6):1448-1457
pubmed: 29066265
PLoS One. 2010 Feb 15;5(2):e9220
pubmed: 20169164
Curr Atheroscler Rep. 2017 Oct 17;19(12):49
pubmed: 29038906
Oman Med J. 2014 Mar;29(2):85-91
pubmed: 24715932
Cardiovasc Drugs Ther. 2016 Oct;30(5):473-483
pubmed: 27618825